Shopping Cart
Remove All
Your shopping cart is currently empty
Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | - | In Stock | |
| 5 mg | $48 | - | In Stock | |
| 10 mg | $88 | - | In Stock | |
| 25 mg | $167 | - | In Stock | |
| 50 mg | $257 | - | In Stock | |
| 100 mg | $358 | - | In Stock | |
| 200 mg | $497 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $56 | - | In Stock |
| Description | Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively. |
| Targets&IC50 | SGLT2 (human):1.95 μM (Ki), SGLT1 (rat):8.57 μM (Ki), SGLT2 (rat):2.14 μM (Ki), SGLT1 (human):43.1 μM (Ki) |
| In vivo | Oral administration of Remogliflozin etabonate (10-30 mg/kg) dose-dependently reduces the levels of FPG and GHb. Oral administration of Remogliflozin etabonate (3-30 mg/kg) dose-dependently increases urine volume and urinary glucose excretion[2]. |
| Synonyms | GSK-189075A, GSK189075A, GSK-189075, GSK189075, GSK 189075A, GSK 189075 |
| Molecular Weight | 522.59 |
| Formula | C26H38N2O9 |
| Cas No. | 442201-24-3 |
| Smiles | CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O |
| Relative Density. | 1.31 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90.0 mg/mL (172.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.31 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.